DEXCOM INC (DC4.DE) Stock Fundamental Analysis
FRA:DC4 - Deutsche Boerse Ag - US2521311074 - Common Stock - Currency: EUR
Taking everything into account, DC4 scores 6 out of 10 in our fundamental rating. DC4 was compared to 56 industry peers in the Health Care Equipment & Supplies industry. DC4 scores excellent on profitability, but there are some minor concerns on its financial health. DC4 is valued quite expensive, but it does show an excellent growth. With these ratings, DC4 could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
DC4 had positive earnings in the past year.
DC4 had a positive operating cash flow in the past year.
In the past 5 years DC4 has always been profitable.
DC4 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 7.93%, DC4 belongs to the best of the industry, outperforming 82.14% of the companies in the same industry.
With an excellent Return On Equity value of 23.61%, DC4 belongs to the best of the industry, outperforming 89.29% of the companies in the same industry.
The Return On Invested Capital of DC4 (14.54%) is better than 94.64% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DC4 is above the industry average of 8.20%.
The last Return On Invested Capital (14.54%) for DC4 is above the 3 year average (11.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.93% | ||
| ROE | 23.61% | ||
| ROIC | 14.54% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
1.3 Margins
Looking at the Profit Margin, with a value of 12.90%, DC4 belongs to the top of the industry, outperforming 80.36% of the companies in the same industry.
In the last couple of years the Profit Margin of DC4 has grown nicely.
Looking at the Operating Margin, with a value of 16.54%, DC4 is in the better half of the industry, outperforming 76.79% of the companies in the same industry.
In the last couple of years the Operating Margin of DC4 has grown nicely.
The Gross Margin of DC4 (60.72%) is comparable to the rest of the industry.
DC4's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.54% | ||
| PM (TTM) | 12.9% | ||
| GM | 60.72% |
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DC4 is creating some value.
The number of shares outstanding for DC4 has been increased compared to 1 year ago.
Compared to 5 years ago, DC4 has more shares outstanding
The debt/assets ratio for DC4 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.90 indicates that DC4 is not in any danger for bankruptcy at the moment.
DC4's Altman-Z score of 5.90 is amongst the best of the industry. DC4 outperforms 85.71% of its industry peers.
The Debt to FCF ratio of DC4 is 4.35, which is a neutral value as it means it would take DC4, 4.35 years of fcf income to pay off all of its debts.
DC4 has a better Debt to FCF ratio (4.35) than 62.50% of its industry peers.
A Debt/Equity ratio of 0.57 indicates that DC4 is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.57, DC4 is not doing good in the industry: 66.07% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.57 | ||
| Debt/FCF | 4.35 | ||
| Altman-Z | 5.9 |
ROIC/WACC1.78
WACC8.17%
2.3 Liquidity
DC4 has a Current Ratio of 1.50. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.50, DC4 is in line with its industry, outperforming 42.86% of the companies in the same industry.
A Quick Ratio of 1.32 indicates that DC4 should not have too much problems paying its short term obligations.
DC4 has a Quick ratio of 1.32. This is in the better half of the industry: DC4 outperforms 64.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.32 |
3. Growth
3.1 Past
DC4 shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.60%.
DC4 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 29.25% yearly.
Looking at the last year, DC4 shows a quite strong growth in Revenue. The Revenue has grown by 9.11% in the last year.
Measured over the past years, DC4 shows a very strong growth in Revenue. The Revenue has been growing by 22.27% on average per year.
EPS 1Y (TTM)-0.6%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%0%
Revenue 1Y (TTM)9.11%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%12.49%
3.2 Future
The Earnings Per Share is expected to grow by 22.56% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 14.01% on average over the next years. This is quite good.
EPS Next Y25.5%
EPS Next 2Y25.23%
EPS Next 3Y24.56%
EPS Next 5Y22.56%
Revenue Next Year14.72%
Revenue Next 2Y15.07%
Revenue Next 3Y14.93%
Revenue Next 5Y14.01%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 49.51, which means the current valuation is very expensive for DC4.
Compared to the rest of the industry, the Price/Earnings ratio of DC4 is on the same level as its industry peers.
DC4 is valuated expensively when we compare the Price/Earnings ratio to 26.82, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 31.54, which means the current valuation is very expensive for DC4.
DC4's Price/Forward Earnings ratio is in line with the industry average.
DC4's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 36.21.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.51 | ||
| Fwd PE | 31.54 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as DC4.
The rest of the industry has a similar Price/Free Cash Flow ratio as DC4.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.63 | ||
| EV/EBITDA | 33.3 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DC4 does not grow enough to justify the current Price/Earnings ratio.
DC4 has an outstanding profitability rating, which may justify a higher PE ratio.
DC4's earnings are expected to grow with 24.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.94
PEG (5Y)1.69
EPS Next 2Y25.23%
EPS Next 3Y24.56%
5. Dividend
5.1 Amount
DC4 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:DC4 (8/1/2025, 7:00:00 PM)
71.3
-0.76 (-1.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.23%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap27.96B
Analysts85.29
Price Target88.34 (23.9%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.87%
Min EPS beat(2)-11.66%
Max EPS beat(2)-4.09%
EPS beat(4)2
Avg EPS beat(4)-1.25%
Min EPS beat(4)-11.66%
Max EPS beat(4)9.24%
EPS beat(8)6
Avg EPS beat(8)14.5%
EPS beat(12)9
Avg EPS beat(12)12.8%
EPS beat(16)11
Avg EPS beat(16)12.29%
Revenue beat(2)0
Avg Revenue beat(2)-0.7%
Min Revenue beat(2)-1.2%
Max Revenue beat(2)-0.19%
Revenue beat(4)0
Avg Revenue beat(4)-2.01%
Min Revenue beat(4)-4.99%
Max Revenue beat(4)-0.19%
Revenue beat(8)2
Avg Revenue beat(8)-0.7%
Revenue beat(12)4
Avg Revenue beat(12)-0.65%
Revenue beat(16)6
Avg Revenue beat(16)-0.11%
PT rev (1m)-0.56%
PT rev (3m)-1.99%
EPS NQ rev (1m)-0.71%
EPS NQ rev (3m)-7.25%
EPS NY rev (1m)0.06%
EPS NY rev (3m)0.53%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.51 | ||
| Fwd PE | 31.54 | ||
| P/S | 7.71 | ||
| P/FCF | 55.63 | ||
| P/OCF | 33.19 | ||
| P/B | 14.12 | ||
| P/tB | 14.9 | ||
| EV/EBITDA | 33.3 |
EPS(TTM)1.44
EY2.02%
EPS(NY)2.26
Fwd EY3.17%
FCF(TTM)1.28
FCFY1.8%
OCF(TTM)2.15
OCFY3.01%
SpS9.24
BVpS5.05
TBVpS4.79
PEG (NY)1.94
PEG (5Y)1.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.93% | ||
| ROE | 23.61% | ||
| ROCE | 18.47% | ||
| ROIC | 14.54% | ||
| ROICexc | 53.32% | ||
| ROICexgc | 60.37% | ||
| OM | 16.54% | ||
| PM (TTM) | 12.9% | ||
| GM | 60.72% | ||
| FCFM | 13.87% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexcg growth 3Y55.18%
ROICexcg growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.57 | ||
| Debt/FCF | 4.35 | ||
| Debt/EBITDA | 1.42 | ||
| Cap/Depr | 172.69% | ||
| Cap/Sales | 9.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 105.79% | ||
| Profit Quality | 107.47% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.32 | ||
| Altman-Z | 5.9 |
F-Score6
WACC8.17%
ROIC/WACC1.78
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.6%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%0%
EPS Next Y25.5%
EPS Next 2Y25.23%
EPS Next 3Y24.56%
EPS Next 5Y22.56%
Revenue 1Y (TTM)9.11%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%12.49%
Revenue Next Year14.72%
Revenue Next 2Y15.07%
Revenue Next 3Y14.93%
Revenue Next 5Y14.01%
EBIT growth 1Y2.68%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year76.08%
EBIT Next 3Y38.17%
EBIT Next 5Y31.52%
FCF growth 1Y38.27%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y27.88%
OCF growth 3Y30.77%
OCF growth 5Y25.76%